This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

More Breast Cancer Survivors Returning Successfully To Work After Short Term Disability Leave

More than twice as many people who have battled breast cancer are returning to work after short term disability leave, according to internal data from Unum (NYSE:UNM), the leading provider of disability benefits through the workplace.

In 2009, nearly 64 percent of people on short term disability leave due to breast cancer returned to work, a number that has climbed steadily from 28.8 percent in 2001. The encouraging increase likely signals improved treatments and outcomes for many people fighting breast cancer, said Cheryl Greaney, vice president of Medical Operations for Unum.

“The people behind these numbers are facing some of the most difficult times in their lives, and the ability to return to work offers a sense of normalcy and routine that can be truly beneficial,” she said.

“Increases in early detection coupled with newer approaches have reduced severity of treatment for many early stage breast cancers. Many of the newer chemotherapy agents are more targeted, although not free from side effects, and can be easier to tolerate than agents typically used 5 to 10 years ago,” Greaney said.

The trend is different, however, for those on long term disability leave due to breast cancer. After rising gradually for several years, the percentage who returned to work leveled off and then fell. In 2001, 47 percent returned to work. That number climbed to a high of 54.8 percent in 2006, then dropped to 50.1 percent by 2009.

“The reasons for this are not entirely clear, but this trend may be influenced by some of the same factors that have improved success in returning to work for people on short term disability,” Greaney said. “As treatments become more effective and outcomes improve for many with earlier stage disease, the pool of people who eventually move to long term disability may necessarily be those who have later stage cancer and as a result require more aggressive, debilitating treatments.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%
YHOO $27.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs